- Home
- ZIMV vs KROS Comparison
ZIMV vs KROS Comparison
Compare ZIMV & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZIMV
- KROS
- Stock Information
- Founded
- ZIMV 2021
- KROS 2015
- Country
- ZIMV United States
- KROS United States
- Employees
- ZIMV N/A
- KROS N/A
- Industry
- ZIMV Biotechnology: Electromedical & Electrotherapeutic Apparatus
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- ZIMV Health Care
- KROS Health Care
- Exchange
- ZIMV Nasdaq
- KROS Nasdaq
- Market Cap
- ZIMV 532.4M
- KROS 565.0M
- IPO Year
- ZIMV N/A
- KROS 2020
- Fundamental
- Price
- ZIMV $18.85
- KROS $15.59
- Analyst Decision
- ZIMV Hold
- KROS Buy
- Analyst Count
- ZIMV 3
- KROS 14
- Target Price
- ZIMV $14.50
- KROS $20.56
- AVG Volume (30 Days)
- ZIMV 651.9K
- KROS 487.1K
- Earning Date
- ZIMV 10-29-2025
- KROS 11-05-2025
- Dividend Yield
- ZIMV N/A
- KROS N/A
- EPS Growth
- ZIMV N/A
- KROS N/A
- EPS
- ZIMV N/A
- KROS 0.47
- Revenue
- ZIMV $443,402,000.00
- KROS $232,844,000.00
- Revenue This Year
- ZIMV $2.49
- KROS $5,579.44
- Revenue Next Year
- ZIMV $1.26
- KROS N/A
- P/E Ratio
- ZIMV N/A
- KROS $33.50
- Revenue Growth
- ZIMV N/A
- KROS 85820.30
- 52 Week Low
- ZIMV $8.15
- KROS $9.12
- 52 Week High
- ZIMV $19.01
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- ZIMV 76.07
- KROS 60.26
- Support Level
- ZIMV $18.84
- KROS $15.38
- Resistance Level
- ZIMV $19.01
- KROS $16.07
- Average True Range (ATR)
- ZIMV 0.07
- KROS 0.66
- MACD
- ZIMV -0.27
- KROS 0.08
- Stochastic Oscillator
- ZIMV 5.88
- KROS 76.54
About ZIMV ZimVie Inc.
ZimVie Inc is focused on the dental and spine markets and their respective growth drivers such as implants, surgical tools, bone graft substitutes, spinal fusion implants, non-fusion alternatives, and digital care management solutions. Business is organized into two operating segments the spine products segment and the dental products segment.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.